Skip Nav Destination

Therapeutic Research and Development

Translational studies that investigate molecular targets, lead compounds, and experimental therapies in a preclinical setting

SUBMIT TO JOURNAL

Latest in Therapeutic Research and Development

June 16 2025

Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities

Sanja Karovic, Erik Dvergsten et al.

The Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program’s OP-35 rule penalizes health systems that have a higher-than-expected rate of emergency department (ED) visits or inpatient admissions for 10 potentially preventable conditions within 30 days of receiving chemotherapy. ...

June 09 2025

Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Olga Zamulko, Vidhya Karivedu et al.

Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) portends a poor prognosis. DNA pathway repair mutations in HNSCC are associated with higher tumor mutational burden rates and immune checkpoint inhibitor response. PARP inhibitors (PARPi) induce ssDNA breaks and are efficacious in cancers with DNA ...

June 06 2025

Protein-level analysis of differential response to chemotherapy in triple negative breast cancer identifies CYP1B1 as a biomarker for chemotherapy resistance.

F. Scott Heinemann, Paul D. Gershon

Resistance to chemotherapy is a critical challenge in triple negative breast cancer (TNBC). In this study, the proteomes of pretreatment core biopsy samples from 16 TNBC patients with differential response to neoadjuvant chemotherapy (NAC) were analyzed by nanoLC-MS/MS to identify biomarkers of intrinsic chemotherapy ...

June 06 2025

Histone deacetylase inhibitors target DNA replication regulators and replication stress in Ewing sarcoma cells

Stacia L. Koppenhafer, Elizabeth L. Geary et al.

Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase ...

June 06 2025

Targeting the Glucose–Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer Growth

Simbarashe Mazambani, Seong-Ho Park et al.

Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this ...

June 04 2025

Cisplatin-induced APE2 overexpression disrupts MYH9 function and causes hearing loss

Qingzhu Wang, Eric E. Irons et al.

Cisplatin remains a cornerstone chemotherapy for many solid tumors but is limited by dose-limiting toxicities, including nephrotoxicity, peripheral neuropathy, and ototoxicity — the latter of which disproportionately affects pediatric patients and lacks effective prevention strategies. Although therapeutic approaches to ...

June 04 2025

Repurposing Amiodarone for Bladder Cancer Treatment

Francisco J. Roa, Maria Roubelakis et al.

Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for new therapeutic strategies. Drug repurposing has emerged as a promising approach in cancer treatment, with various studies ...

June 03 2025

High-throughput drug screening of clear cell ovarian cancer organoids reveal vulnerability to proteasome inhibitors and dinaciclib and identify AGR2 as a therapeutic target

Takuma Yoshimura, Takashi Kamatani et al.

There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determine novel therapeutic targets based on the biological characteristics of CCC through ...

May 30 2025

A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2

Monica M. Mita, Alain C. Mita et al.

May 27 2025

Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study

Kentaro Sawada, Riu Yamashita et al.

Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigated the association between the microbiome, clinical features, and ICI efficacy across ...

View all Therapeutic Research and Development articles

Topics in Therapeutic Research and Development

Expand/Collapse Section ALTERNATIVE MEDICINE
Expand/Collapse Section BIOLOGICAL AGENTS & THERAPIES
- Antireceptors
- Antibody-drug conjugates
- Aptamers, ribozymes, or DNAzymes
- Antisense oligonucleotides
- Cell-based therapeutics
- Differentiation therapy
- Gene therapy
- Stem cell therapies
- Bispecific antibodies
Expand/Collapse Section CHEMOTHERAPY
- Adjuvant chemotherapy
- Biochemical modulators of the therapeutic index
- Combination chemotherapy
- Differentiation therapy
- Novel drug delivery systems
Expand/Collapse Section DRUG MECHANISMS
- Cell cycle mechanisms of anticancer drug action
- Cellular responses to anticancer drugs
- Drug-mediated stimulation of cell death pathways
- p53 and anticancer drug action
- Modulation of DNA repair
Expand/Collapse Section DRUG RESISTANCE
- Biochemistry of membrane metabolism and transport
- Drug transport and metabolism
- Glutathione metabolism
- Non-transporter-based drug resistance
- Novel mechanisms
- Regulation of gene expression in drug resistance
- Reversal of drug resistance
- Transporter-based drug resistance
- Clinical drug resistance
Expand/Collapse Section DRUG TARGETS
- Cell surface receptor drug targets
- Oncoprotein & tumor suppressor drug targets
- Protein kinase & phosphatase drug targets
Expand/Collapse Section NANOPARTICLE AGENTS
Expand/Collapse Section PHARMACOLOGY
- Cellular pharmacology
- Molecular pharmacology
- Pharmacogenetics/pharmacogenomics
- Preclinical toxicology
- Pharmacokinetics and pharmacodynamics
- Biodistribution/toxicology
Expand/Collapse Section SMALL MOLECULE AGENTS
- Alkylating agents
- DNA-reactive agents
- Epigenetic-targeted agents
- Kinase inhibitors
- Phosphatase inhibitors
- HDAC & methyltransferase inhibitors
- Platinum complexes
- Proteasome inhibitors
- Retinoids
- Topoisomerase agents
- Tubulin agents
Expand/Collapse Section TRANSLATIONAL RESEARCH

Therapeutic Research and Development

Topics in Therapeutic Research and Development

AACR Journals

This Feature Is Available To Subscribers Only